Skip to main content

Table 1 Anthropometrics, clinical characteristics and lipid profile of patients with type 2 diabetes and control subjects

From: Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes

 

Type 2 diabetes phenotype A (n = 77)

Type 2 diabetes phenotype B (n = 45)

Control group

ANOVA

(n = 54)

p-value

Age (years)

60 ± 11

56 ± 11 a

56 ± 14 a

0.108

Male (%)

65.9

64.6

57.4 a, b

<0.001

BMI (kg/m2)

29.6 ± 6.2

31.1 ± 4 a

25.9 ± 3.6 a, b

<0.001

Waist (cm)

104 ± 15

108 ± 13 a

92 ± 11 a, b

<0.001

Diabetes duration (years)

12 ± 11

9 ± 8 a

-

 

Insulin use (%)

58

52 a

-

 

Lipid lowering drugs (%)

30

28

-

 

HbA1c (%)

9.1 ± 2.1

9.6 ± 2.3 a

5.3 ± 0.6 a, b

<0.001

Hypertension (%) 1

69.4

68.2

-

 

Retinopathy (%)

29.6

29.5

-

 

Albuminuria (%)

24

29.6 a

-

 

Coronary heart disease (%) 2

5.6

15.9 a

-

 

Total cholesterol (mmol/L)

4.78 ± 1.09

5.64 ± 1.53 a

5.00 ± 0.79 b

0.004

Triglycerides (mmol/L)

1.46 ± 0.79

3.89 ± 3.30 a

0.87 ± 0.37 a,b

<0.001

VLDLc (mmol/L)

0.65 ± 0.30

1.43 ± 1.12 a

0.40 ± 0.17 a,b

<0.001

LDLc (mmol/L)

2.86 ± 0.95

3.10 ± 0.96 a

2.94 ± 0.66 b

0.281

HDLc (mmol/L)

1.28 ± 0.33

1.02 ± 0.27 a

1.64 ± 0.37 a,b

<0.001

NEFA (mmol/L)

0.64 ± 0.29

0.90 ± 0.48

0.41 ± 0.19 a,b

<0.001

apoB (g/L)

0.93 ± 0.32

1.09 ± 0.28 a

0.80 ± 0.19 a,b

<0.001

apoA-I (g/L)

1.46 ± 0.24

1.37 ± 0.25 a

1.57 ± 0.31 a,b

0.001

apoA-II (g/L)

0.33 ± 0.07

0.34 ± 0.06

0.35 ± 0.05

0.081

LDL size (nm)

26.0 ± 0.4

25.0 ± 0.4 a

26.3 ± 0.1 b

<0.001

  1. a, P < 0.05 vs phenotype A patients; b, P < 0.05 vs phenotype B patients. 1 Hypertension was defined as a systolic blood pressure of ≥140 mm Hg, a diastolic blood pressure of ≥90 mm Hg or those who were receiving antihypertensive therapy at the time of examination. 2 Coronary Heart Disease (CHD) was defined as documented diagnosis of CHD, self-reported positive history of CHD or ECG positive for CHD.